Skip to main content
TipRanks
Go Ultimate75% OFF

Nanollose Ltd. (NC6) AI Stock Analysis

3 Followers
AU:NC6

Nanollose Ltd.

(ASX:NC6)

Select Model
Rating:46Neutral
Price Target:AUD 0.06â–¼(-1.67% Downside)
Action:reiterated
Date:09/26/26

The overall score is heavily pressured by the company's dire financial state, marked by zero revenue and accelerating cash burn that threatens its recently recapitalized balance sheet. The lack of earnings and dividends further weighs on the valuation. The primary support for the score comes from positive technical momentum, with the stock trading above key moving averages, though this is tempered by an overbought stochastic signal.

Positive Factors
Differentiated cellulose technologyPlant-free cellulose produced through microbial fermentation gives Nanollose a differentiated platform aligned with sustainable materials demand. If commercialised, this technology can support textile and industrial applications beyond a single product, creating longer-term growth optionality.
Negative Factors
Persistent unprofitabilityRecurring losses across all reported years show that the business has not yet established a profitable operating model. Negative EBIT and EBITDA limit internally generated funding, make commercial scaling more difficult, and leave future progress dependent on improved economics or additional capital.

Nanollose Ltd. (NC6) vs. iShares MSCI Australia ETF (EWA)

-20%0%20%40%60%80%AU:NC6+27.66%EWA+14.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 24.59M
Dividend Yield
―
Average Volume (3M)
92.04K
Price to Earnings (P/E)
-8.3
Beta (1Y)
-0.04
Revenue Growth
―
EPS Growth
-5.88%
Country
Australia
Employees
1
Sector
Consumer Cyclical
Sector Strength
61
Industry
Biotechnology

Nanollose Ltd. Business Overview & Revenue Model

Company Description

Nanollose Limited is an Australian biomaterials enterprise dedicated to the research, development, and commercialization of microbial nanocellulose technology. Its product line features Nullarbor Fibre, an innovative lyocell fibre produced without re...

Nanollose Ltd. Financial Statement Overview

Summary

Financial health is critically weak. The company has zero revenue, accelerating cash burn (TTM operating cash flow of -A$1.8M), and deeply negative margins. The only positive is a recent recapitalization that restored a modest positive equity of A$1.2M with negligible debt, but the high cash consumption rate threatens this capital base quickly.

Income Statement

8Very Negative

Balance Sheet

35Negative

Cash Flow

5Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue00012.50K412.16K224.61K
Gross Profit-14.56K-14.57K-35.83K-779.20K58.29K-223.55K
EBITDA-2.68M-2.68M-1.59M-1.10M-1.68M-1.72M
Net Income-2.39M-2.39M-1.43M-1.16M-1.35M-1.57M
Balance Sheet
Total Assets1.42M1.42M747.79K241.95K633.24K1.91M
Cash, Cash Equivalents and Short-Term Investments1.33M1.33M617.32K138.75K548.25K1.59M
Total Debt7,1727,17213.09K42.53K11.52K38.09K
Total Liabilities225.40K225.40K351.38K465.64K181.61K181.51K
Stockholders Equity1.20M1.20M396.41K-223.69K451.63K1.73M
Cash Flow
Free Cash Flow-1.80M-1.80M-1.10M-900.95K-1.01M-1.39M
Operating Cash Flow-1.80M-1.80M-1.10M-900.95K-1.01M-1.38M
Investing Cash Flow00015.97K0-5,352
Financing Cash Flow2.51M2.51M1.58M475.49K-26.57K-32.69K

Nanollose Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.06

Price Trends

50DMA0.07Negative
100DMA0.07Negative
200DMA0.07Negative

Market Momentum

MACD-0.00Positive
RSI19.29Positive
STOCH-29.17Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NC6, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 19.29 is Positive, neither overbought nor oversold. The STOCH value of -29.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NC6.

Nanollose Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

AU:NC6 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$18.38B12.79-2.54%3.03%1.52%-15.83%
AU:AVEAU:AVE49NeutralAUD 46.36M-8.00-211.39%―-46.59%9.09%
AU:TRPAU:TRP47NeutralAUD 5.86M-1.24-52.04%―32.22%-26.53%
AU:NC6AU:NC646NeutralAUD 24.59M-8.33-465.54%――-5.88%
AU:OCCAU:OCC44NeutralAUD 155.26M-10.75-36.83%―51.07%-47.63%
AU:BOTAU:BOT38UnderperformAUD 22.10M-0.25-118.74%―499.47%31.20%
AU:ADOAU:ADO31UnderperformAUD 52.28M-11.43-77.75%―-51.74%24.00%

* Consumer Cyclical Sector Average

Performance Comparison

-50%0%50%100%150%AU:NC6AU:OCCAU:TRPAU:ADOAU:AVEAU:BOTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:NC6 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:NC6Nanollose Ltd.0.060.0120.00%
AU:OCCOrthocell Ltd0.56-0.44-44.50%
AU:TRPTissue Repair Ltd0.11-0.19-63.33%
AU:ADOAnteoTech Ltd0.02-0.00-15.79%
AU:AVEAvecho Biotechnology Limited0.010.0030.00%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.11-91.67%

Nanollose Ltd. Corporate Events

Nanollose Reports Results From 2026 Annual General Meeting

Nov 17, 2026

Nanollose held its 2026 Annual General Meeting in Nedlands, Western Australia, on 17 November 2026, with all resolutions decided by poll. Voting recorded 89.70% in favour of adopting the remuneration report, 92.86% for Winton Willesee’s re-election a...

Nanollose fast-tracks WA pilot facility to support microbial cellulose commercialisation

Oct 29, 2026

Nanollose has refined its scale-up strategy to focus on a single, company-controlled pilot facility in Western Australia to produce microbial cellulose pulp, replacing plans for a larger demonstration line and reducing capital intensity on the path t...

Nanollose Secures Stage 1 Pilot Equipment as Biomaterials Scale-Up Accelerates

Oct 25, 2026

Nanollose has completed procurement for all equipment required for Stage 1 of its pilot facility program in Western Australia, marking a shift from planning to execution as it builds an in-house environment to scale and optimise its microbial cellulo...

Nanollose Issues New Tranche of Unlisted Options

Oct 8, 2026

Nanollose Ltd., listed on the ASX under ticker NC6, operates in the advanced materials and biotechnology sector, developing sustainable, plant-free cellulose-based materials for use in textiles and other industrial applications. The company targets e...

Nanollose Expands ASX-Listed Share Base With New NC6 Securities

Sep 15, 2026

Nanollose Ltd. has lodged an application with the ASX for the quotation of an additional 500,000 ordinary fully paid shares under its NC6 ticker. The new securities, issued on 15 September 2026, will be admitted to trading alongside the company’s exi...

Nanollose seeks ASX quotation for 300,000 new shares

Sep 4, 2026

Nanollose Limited has applied for quotation of 300,000 new ordinary fully paid shares on the ASX under code NC6, with an issue date of 4 September 2026. The modest increase in quoted securities signals a small capital or equity adjustment that margin...

Nanollose widens annual loss but boosts net tangible assets

Aug 31, 2026

Nanollose Limited reported a net loss after tax of $2.39 million for the year ended 30 June 2026, a 68% increase from the prior year’s loss of $1.43 million, while revenue from ordinary activities remained at nil.The company’s net tangible assets ros...

Nanollose Issues 3 Million Unquoted Employee Options Under Incentive Scheme

Aug 20, 2026

Nanollose Limited has notified the market of the issue of 3,000,000 unquoted employee options under its incentive scheme. The options, in three tranches of 1,000,000 each, were issued on August 21, 2026 and are subject to transfer restrictions, meani...

Nanollose Streamlines Scale-Up with Single Pilot Facility to Accelerate Commercial Partnerships

Aug 20, 2026

Nanollose Ltd. is an advanced biomaterials company focused on scaling technology that converts microbial cellulose into fibres, fabrics and other materials for industrial use. Rather than investing in full-scale manufacturing, the company aims to com...

Nanollose Adds New Shares to ASX Quotation After Option Conversions

Aug 18, 2026

Nanollose Ltd. has lodged an application with the ASX for quotation of 2,544 new ordinary fully paid shares under its NC6 ticker. The shares, issued on 18 August 2026 following the exercise or conversion of existing options or other convertible secur...

Nanollose Seeks ASX Quotation for Additional 70,000 Shares

Aug 18, 2026

Nanollose Ltd. has applied for quotation of an additional 70,000 ordinary fully paid shares on the ASX, with an issue date of 18 August 2026. The modest increase in quoted securities slightly expands the company’s free float and may improve share liq...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 26, 2026